A New VISTA on combination therapy for negative checkpoint regulator blockade

Negative checkpoint regulators function to restrain T cell responses to maintain tolerance and limit immunopathology. However, in the setting of malignancy, these pathways work in concert to promote immune-mediate escape leading to the development of a clinically overt cancer. In the recent years, c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal for immunotherapy of cancer Jg. 4; H. 1; S. 86
Hauptverfasser: Deng, Jie, Le Mercier, Isabelle, Kuta, Anna, Noelle, Randolph J.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London BMJ Publishing Group Ltd 20.12.2016
BioMed Central
BioMed Central Ltd
BMJ Publishing Group LTD
BMJ Publishing Group
Schlagworte:
ISSN:2051-1426, 2051-1426
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Negative checkpoint regulators function to restrain T cell responses to maintain tolerance and limit immunopathology. However, in the setting of malignancy, these pathways work in concert to promote immune-mediate escape leading to the development of a clinically overt cancer. In the recent years, clinical trials demonstrating the efficacy of blocking antibodies against these molecules have invigorated the field of immunotherapy. In this review, we discuss the current understanding on established NCR blockade and how strategic combination therapy with anti-VISTA antibody can be used to target multiple non-redundant NCR pathways.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2051-1426
2051-1426
DOI:10.1186/s40425-016-0190-5